证券研究报告·公司深度研究·化学制药 信立泰（002294） 慢病领域创新龙头，心衰重磅 JK07 潜力大 2026 年 04 月 01 日 买入（首次） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 3,365 | 4,012 | 4,643 | 5,563 | 6,775 | | 同比（%） | (3.35) | 19.22 | 15.72 | 19.81 | 21.79 | | 归母净利润（百万元） | 580.07 | 601.57 | 678.55 | 901.75 | 1,276.67 | | 同比（%） | (8.95) | 3.71 | 12.80 | 32.89 | 41.58 | | EPS-最新摊薄（元/股） | 0.52 | 0.54 | 0.61 | 0.81 | 1.15 | | P/E（现价&最新摊薄） | 111.66 | 107.67 | 95.46 | 71.83 | 50.73 | [T ...

证 券 研 究 报 告 信立泰（002294）重大事项点评 强推（上调） 递交港股招股说明书，加快国际化进程 目标价：85.5 元 | | | 华创证券研究所 证券分析师：郑辰 事项： ❖ 近期，信立泰向香港联交所递交了发行 H 股股票并在香港联交所主板挂牌上 市的申请，加快公司国际化进程。 评论： [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 4,012 | 4,460 | 5,161 | 6,476 | | 同比增速(%) | 19.2% | 11.2% | 15.7% | 25.5% | | 归母净利润(百万) | 602 | 640 | 692 | 857 | | 同比增速(%) | 3.7% | 6.4% | 8.1% | 24.0% | | 每股盈利(元) | 0.54 | 0.57 | 0.62 | 0.77 | | 市盈率(倍) | 115 | 108 | 100 | 80 | | 市净率(倍) | 7.9 | 7.8 ...

证 券 研 究 报 告 信立泰（002294）重大事项点评 强推（上调） 递交港股招股说明书，加快国际化进程 目标价：85.5 元 事项： ❖ 近期，信立泰向香港联交所递交了发行 H 股股票并在香港联交所主板挂牌上 市的申请，加快公司国际化进程。 公司研究 化学制剂 2026 年 03 月 30 日 | | | 华创证券研究所 证券分析师：郑辰 邮箱：zhengchen@hcyjs.com 执业编号：S0360520110002 评论： [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 4,012 | 4,460 | 5,161 | 6,476 | | 同比增速(%) | 19.2% | 11.2% | 15.7% | 25.5% | | 归母净利润(百万) | 602 | 640 | 692 | 857 | | 同比增速(%) | 3.7% | 6.4% | 8.1% | 24.0% | | 每股盈利(元) | 0.54 | 0.57 ...

Group 1: Oil Crisis Historical Review and Investment Insights - The oil crisis typically begins with geopolitical conflicts and escalates due to expectations of supply disruptions, leading to short-term price spikes and long-term price increases [1][12] - The macroeconomic impact of oil crises has historically led to inflation followed by stagnation or similar conditions, with the 1970s crisis resulting in recession and stagflation in the US, while the 2022 situation only saw a technical recession [1][12] - Market narratives have evolved, reflecting learning effects from past crises, with shifts from valuation model failures to asset worship and supply-side reforms [1][12] - Asset performance during crises shows that commodities like oil benefit directly, while equities face valuation pressures, and bonds initially decline before rising due to inflation expectations [1][12] Group 2: Logistics and Transportation Sector - The daily traffic volume at Ganqimaodu Port has shown a steady recovery, with an average of 1,351 vehicles per day from March 16 to March 22, 2026, marking a 55.7% year-on-year increase [5][17] - The port's cargo throughput has also increased significantly, with a 35% year-on-year growth to 10.24 million tons as of March 15, 2026 [5][17] - Short-distance freight rates have stabilized and increased, averaging 65 RMB per ton in 2026, reflecting an 8.3% year-on-year rise [6][17] Group 3: Company-Specific Insights - Jiayou International reported a revenue of 2.486 billion RMB in Q3 2025, a 30.61% year-on-year increase, driven by the recovery of cross-border business and rising prices of coking coal [7][18] - The company is expected to benefit from the integration of mining services, logistics, customs clearance, and coal sales, enhancing its competitive advantage in the cross-border logistics market [7][18] - Northern International is projected to benefit from rising coking coal and European natural gas prices, with a target price of 18 RMB based on a 24x PE ratio for 2026 [31][32] Group 4: Social Services Sector - The social services sector is experiencing a policy-driven boost in consumer spending, particularly in travel and hospitality, with recommendations for various hotel and tourism companies [19][20] - The education sector is also seeing robust demand, with significant expansion opportunities in high school education and vocational training [20][23] - Traditional retail is undergoing transformation, with new consumption patterns emerging and companies adapting to changing market dynamics [20][23]

创新步入快速收获期，国际化开启新征程 信立泰(002294) 信立泰递交 H 股上市发行申请公告点评 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 余文心(分析师) | 021-38676666 | yuwenxin@gtht.com | S0880525040111 | | 余克清(分析师) | 010-56760093 | yukeqing@gtht.com | S0880525120002 | | 陈铭(分析师) | 021-23219164 | chenming7@gtht.com | S0880525100004 | | 廖博闻(分析师) | 021-23187268 | liaobowen@gtht.com | S0880526030005 | 本报告导读： 信立泰是国内聚焦心肾代谢综合征（CKM）慢病领域的创新药龙头企业，截止 2026 年 2 月，信立泰拥有 6 款 1 类创新药获批上市，重磅临床管线 JK07 具备心衰治疗 潜力。 投资要点： | [Table_Finance] 财务摘要(百万元) | 2 ...

Investment Rating - The investment rating for the company is "Accumulate" with a target price of 66.68 CNY [6]. Core Insights - The company, Xinlitai, is a leading innovative pharmaceutical enterprise focusing on chronic diseases related to heart and kidney metabolic syndrome (CKM). By February 2026, it is expected to have six Class 1 innovative drugs approved for market, with the key clinical pipeline JK07 showing potential for heart failure treatment [2]. - The company ranks first globally in the number of new molecular entity (NME) hypertension drugs approved since 2012 and is recognized for its two pillar hypertension products, which are expected to drive significant sales growth [12]. - The potential market for heart failure treatment, particularly for JK07, is estimated to exceed 100 billion USD, indicating substantial commercial potential [12]. Financial Summary - Total revenue is projected to grow from 3,365 million CNY in 2023 to 6,478 million CNY by 2027, reflecting a compound annual growth rate (CAGR) of approximately 21.4% [4]. - Net profit attributable to shareholders is expected to increase from 580 million CNY in 2023 to 1,003 million CNY in 2027, with a CAGR of about 21.4% [4]. - Earnings per share (EPS) is forecasted to rise from 0.52 CNY in 2023 to 0.90 CNY in 2027, indicating a strong growth trajectory [4]. Market Position - Xinlitai is positioned as a leader in the hypertension treatment sector, with its product "Xinlitai" being the best-selling ARB drug in China as of 2024, and "Xinchao" being the first ARNi drug approved in China and the second globally [12]. - The company has a robust pipeline in lipid metabolism, targeting various key indicators and treatment modalities, which enhances its comprehensive management of dyslipidemia [12].

Summary of the Conference Call for 信立泰 Company Overview - 信立泰 is a leading company in the field of heart-kidney metabolic syndrome in China, currently undergoing an accelerated innovation transformation [3][4] Innovation Transformation Progress - The proportion of innovative drug revenue is expected to rise from 27% in 2023 to 46% in Q1-Q3 of 2025, indicating a significant acceleration in innovation transformation [2][3] - R&D investment has consistently exceeded 25% of total revenue since 2023, with cumulative investments surpassing 5 billion yuan since 2020 [3][2] Future Performance Expectations - Revenue projections for 2025-2027 are 4.34 billion yuan, 5.04 billion yuan, and 5.99 billion yuan, representing year-on-year growth of 8%, 16%, and 19% respectively [3][2] - Net profit attributable to the parent company is expected to reach 640 million yuan, 770 million yuan, and 950 million yuan for the same years, with growth rates of 6%, 21%, and 23% respectively [3][2] - The DCF valuation suggests a reasonable market value of approximately 78.4 billion yuan, with a target price of 70.36 yuan [2][11] Core Products and Market Position - The core ARNI innovative drug, 信超妥, shows superior blood pressure-lowering effects and safety compared to 诺欣妥, with a peak sales expectation of 3-4 billion yuan [2][6] - The high blood pressure product matrix includes 信立坦, 信超妥, 富力坦, and 富力安, with a combined peak sales expectation exceeding 6-7 billion yuan [2][7] Clinical Developments - JK07, a unique bispecific antibody targeting heart failure, showed a 14% absolute improvement in left ventricular ejection fraction in early clinical trials [9][8] - The second phase clinical data for JK07 is expected to be disclosed in H1 2026, with significant market potential comparable to 诺欣妥 [9][8] Strategic Layout in Other Fields - In the kidney and metabolic fields, key products include 恩那罗 for renal anemia and a complete product matrix around 特立帕肽 for osteoporosis [10][10] - The diabetes pipeline includes 信立汀 and PCSK9 inhibitors, which are expected to contribute to future revenue growth [10][10] Investment Rating and Risks - The company is rated "Buy" based on the analysis of product pipelines and sales peak estimates, with a reasonable market value of approximately 78 billion yuan [11][11] - Risks include the uncertainty of JK07's second phase clinical data replicating the positive results of the first phase [11][11]

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical sector, particularly highlighting the potential of the drug JK07 from the company Sinopharm [6]. Core Insights - The pharmaceutical sector is believed to have entered a bottoming phase, with several innovative drug companies showing signs of valuation recovery due to high expectations for overseas sales and recent breakthroughs [3]. - The report emphasizes the importance of innovation and international expansion as the underlying logic for the current pharmaceutical industry cycle, with a focus on innovative drugs and supply chain improvements [4]. - The drug JK07 is positioned to potentially become a blockbuster product, with significant clinical data expected in 2026 that could act as a major catalyst for the company [5][52]. Summary by Sections 1. JK07's Potential - JK07 is expected to rival the drug Entresto, with the potential to become a multi-billion dollar overseas product. The clinical phase II data expected in 2026 is anticipated to be a significant catalyst for Sinopharm [5][52]. - The drug utilizes a unique mechanism involving the protein NRG-1, which activates the ErbB4 receptor, potentially reversing heart failure progression [35][40]. 2. Pharmaceutical Market Review - During the week of March 9-13, the pharmaceutical index decreased by 0.22%, underperforming compared to the ChiNext and CSI 300 indices. The total trading volume for pharmaceuticals was 409.68 billion yuan, accounting for 3.30% of the total market [2][70]. - The report notes that the pharmaceutical sector's performance has been relatively weak, ranking 11th among all industries during the specified week [2][56]. 3. Industry Trends and Hotspots - The report identifies several key trends, including the recovery of valuations for innovative drug companies and the importance of price increases in certain segments, such as medical gloves [3]. - The report highlights the ongoing focus on technological innovation across various sub-sectors, including supply chain management and new therapeutic areas like AI and small nucleic acids [3][4].

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical sector, particularly highlighting the potential of the drug JK07 from the company Sinopharm [6]. Core Insights - The pharmaceutical sector is believed to have entered a bottoming phase, with several innovative drug companies showing signs of valuation recovery due to high expectations for overseas sales and recent breakthroughs [3][4]. - The report emphasizes the importance of innovation and international expansion as the underlying logic for the current pharmaceutical industry cycle, with a focus on innovative drugs and supply chain improvements [4]. Summary by Sections Section 1: JK07's Potential - JK07 is positioned to potentially become a blockbuster drug comparable to Novartis' Entresto, with significant clinical data expected in 2026 [5][52]. - The drug targets heart failure, a condition with substantial unmet clinical needs, and is designed to activate the ErbB4 pathway while blocking ErbB3 signaling, which may enhance its therapeutic efficacy [35][40]. Section 2: Pharmaceutical Market Review - The pharmaceutical index experienced a slight decline of 0.22% during the week of March 9-13, underperforming compared to the ChiNext and CSI 300 indices [53][54]. - The total trading volume for pharmaceuticals was 409.68 billion yuan, accounting for 3.30% of the total market, which is below the historical average of 7.07% since 2013 [70]. Section 3: Market Trends and Valuation - The report notes a decrease in the valuation of the pharmaceutical sector, with a current PE ratio of 30.34, which is below the historical average [67]. - The industry is currently experiencing a valuation premium that is significantly lower than historical averages, indicating potential investment opportunities as valuations normalize [67]. Section 4: Stock Performance - The report highlights the top-performing stocks in the pharmaceutical sector, including Yingke Medical and Chitianhua, which saw significant gains during the week [74]. - Conversely, stocks like Yueshen Health and Yifang Bio-U faced notable declines, indicating a mixed performance across the sector [74].

Investment Rating - The report initiates coverage with a "Buy" rating for the company [4]. Core Insights - The company is a leader in the domestic cardiovascular and renal metabolic syndrome market, accelerating its innovative transformation with nearly 46% of its revenue coming from innovative drugs in the first three quarters of 2025, up from 27% in 2023 [2][36]. - The hypertension product matrix is rich, with key products like Xinchaotuo expected to contribute nearly 4 billion yuan in peak sales [2]. - The global innovative pipeline has significant potential, particularly with JK07, which is expected to break through the treatment bottleneck for heart failure [3]. Summary by Sections Section 1: Domestic Leader in Cardiovascular and Renal Metabolic Syndrome - The company has been deeply engaged in the cardiovascular field for over 20 years, establishing a comprehensive product matrix that includes cardiovascular, renal, metabolic, and orthopedic innovations [2][24]. - The company has launched six innovative drugs and has a robust pipeline with 85 projects under development, ensuring strong future growth [2][40]. Section 2: Rich Hypertension Product Matrix - The prevalence of hypertension is increasing, with the rate rising to 31.6% among adults from 2020 to 2022, indicating a significant market opportunity [49]. - Xinchaotuo, the second ARNI drug globally, is expected to achieve rapid market penetration after its approval in 2025, with peak sales projected at nearly 4 billion yuan [2][58]. - Other innovative drugs like Xinlitai and Fuliantian are also expected to see stable growth and rapid market entry due to their inclusion in medical insurance [2][53]. Section 3: Significant Potential of JK07 - JK07, targeting heart failure patients, has shown promising results in early clinical trials and is expected to be approved by 2029, potentially generating substantial revenue [3][45]. Section 4: Comprehensive Development in Renal, Metabolic, and Orthopedic Fields - The company is advancing its renal anemia product, Ennaruo, which is expected to accelerate its market presence [3][40]. - The metabolic field is also being addressed with innovative drugs like Xinlitai, which is set to be approved in 2024 and included in primary care guidelines by 2025 [3][40]. Section 5: Profit Forecast and Valuation - The company is projected to achieve revenues of 43.37 billion yuan, 50.36 billion yuan, and 59.91 billion yuan from 2025 to 2027, with corresponding net profits of 6.40 billion yuan, 7.72 billion yuan, and 9.48 billion yuan [4][8].